We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

88 hedge funds and large institutions have $176M invested in BioSpecifics Technologies Corp. in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 33 increasing their positions, 34 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

1% more funds holding

Funds holding: 8788 (+1)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

3% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 34

6% less capital invested

Capital invested by funds: $187M → $176M (-$11.3M)

Holders
88
Holders Change
+1
Holders Change %
+1.15%
% of All Funds
2%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
11
Increased
33
Reduced
34
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$19.4M +$1.43M +31,886 +8%
SCM
2
Stonepine Capital Management
Oregon
$16.7M +$7.85M +174,584 +83%
BlackRock
3
BlackRock
New York
$16.1M -$689K -15,324 -4%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$11.8M +$87.2K +1,939 +0.7%
Vanguard Group
5
Vanguard Group
Pennsylvania
$10.2M +$671K +14,933 +7%
ECP
6
Elk Creek Partners
Colorado
$7.31M -$62.4K -1,388 -0.8%
RHJA
7
Rice Hall James & Associates
California
$6.73M -$38.2K -849 -0.5%
AQR Capital Management
8
AQR Capital Management
Connecticut
$5.87M +$837K +18,626 +16%
EAM
9
Eagle Asset Management
Florida
$5.78M -$2.32M -51,649 -28%
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$4.86M -$629K -13,986 -11%
Goldman Sachs
11
Goldman Sachs
New York
$4.62M +$39.6K +882 +0.8%
State Street
12
State Street
Massachusetts
$4.05M -$80K -1,779 -2%
Northern Trust
13
Northern Trust
Illinois
$3.81M +$79.2K +1,763 +2%
NC
14
Northpointe Capital
Michigan
$3.5M -$2.47M -54,947 -41%
Prudential Financial
15
Prudential Financial
New Jersey
$3.26M +$352K +7,821 +12%
JAM
16
JW Asset Management
Florida
$3.19M
Bank of New York Mellon
17
Bank of New York Mellon
New York
$2.99M +$33.9K +755 +1%
Allianz Asset Management
18
Allianz Asset Management
Germany
$2.9M -$813K -18,097 -21%
Wellington Management Group
19
Wellington Management Group
Massachusetts
$2.89M -$240K -5,341 -7%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$2.55M +$232K +5,160 +10%
MOACM
21
Mutual of America Capital Management
New York
$2.4M +$119K +2,652 +5%
Wells Fargo
22
Wells Fargo
California
$2.14M +$197K +4,373 +10%
MCM
23
Matarin Capital Management
New York
$2.12M -$455K -10,125 -17%
RA
24
Royce & Associates
New York
$2.08M +$383K +8,521 +22%
Charles Schwab
25
Charles Schwab
California
$1.86M +$49.4K +1,100 +3%

BSTC Hedge Fund Activity: Q4 2017 in Review

88 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q4 2017, worth a combined $176M — down 6% from $187M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new BSTC positions and 10 closed out — a net gain of 1 holder — while 33 added to existing stakes and 34 trimmed.

The largest buyer was Stonepine Capital Management, adding an estimated $7.85M. The largest seller was Northpointe Capital, cutting an estimated $2.47M.

  • 88 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q4 2017, up from 87 in Q3 2017.
  • Funds reported $176M of BioSpecifics Technologies Corp. stock for Q4 2017, down 6% quarter-over-quarter.
  • 11 funds opened new BioSpecifics Technologies Corp. positions in Q4 2017 and 10 closed out, a net change of +1 holder.
  • The largest BioSpecifics Technologies Corp. buyer in Q4 2017 was Stonepine Capital Management, an estimated $7.85M added.
  • The largest BioSpecifics Technologies Corp. seller in Q4 2017 was Northpointe Capital, an estimated $2.47M sold.

Based on aggregated 13F filings for Q4 2017.